JP6377123B2 - 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 - Google Patents
癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 Download PDFInfo
- Publication number
- JP6377123B2 JP6377123B2 JP2016502187A JP2016502187A JP6377123B2 JP 6377123 B2 JP6377123 B2 JP 6377123B2 JP 2016502187 A JP2016502187 A JP 2016502187A JP 2016502187 A JP2016502187 A JP 2016502187A JP 6377123 B2 JP6377123 B2 JP 6377123B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- pharmaceutical composition
- chlorophenyl
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QPWPHXQCCIMHAL-PICXLURJSA-N CC(C)(C)S(CC(C1CC1)N(C(C(c1cc(Cl)ccc1)O[C@]1(C)Cc(nc2)ccc2C(O)=O)C(/C=C\C(\Cl)=C(/C)\F)=C)C1=O)(=O)=O Chemical compound CC(C)(C)S(CC(C1CC1)N(C(C(c1cc(Cl)ccc1)O[C@]1(C)Cc(nc2)ccc2C(O)=O)C(/C=C\C(\Cl)=C(/C)\F)=C)C1=O)(=O)=O QPWPHXQCCIMHAL-PICXLURJSA-N 0.000 description 1
- IRQSKJQDKUAART-UHFFFAOYSA-N COC(c1cnc(CBr)cc1)=O Chemical compound COC(c1cnc(CBr)cc1)=O IRQSKJQDKUAART-UHFFFAOYSA-N 0.000 description 1
- WNPSSFSXORYRAN-WXOOSPASSA-N C[C@@](CC=C)(C(N(C(CO)C1CC1)C1c(cc2F)ccc2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 Chemical compound C[C@@](CC=C)(C(N(C(CO)C1CC1)C1c(cc2F)ccc2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 WNPSSFSXORYRAN-WXOOSPASSA-N 0.000 description 1
- HKNCPEFDFMIXFA-PZEHHVJRSA-N C[C@@](Cc(nc1)ccc1C(OC)=O)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 Chemical compound C[C@@](Cc(nc1)ccc1C(OC)=O)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 HKNCPEFDFMIXFA-PZEHHVJRSA-N 0.000 description 1
- WNPSSFSXORYRAN-WZCQUIKNSA-N C[C@](CC=C)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 Chemical compound C[C@](CC=C)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 WNPSSFSXORYRAN-WZCQUIKNSA-N 0.000 description 1
- HKNCPEFDFMIXFA-HEXBMGIASA-N C[C@](Cc(nc1)ccc1C(OC)=O)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 Chemical compound C[C@](Cc(nc1)ccc1C(OC)=O)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 HKNCPEFDFMIXFA-HEXBMGIASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784230P | 2013-03-14 | 2013-03-14 | |
| US61/784,230 | 2013-03-14 | ||
| PCT/US2014/026584 WO2014151863A1 (en) | 2013-03-14 | 2014-03-13 | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513660A JP2016513660A (ja) | 2016-05-16 |
| JP2016513660A5 JP2016513660A5 (enExample) | 2017-03-30 |
| JP6377123B2 true JP6377123B2 (ja) | 2018-08-22 |
Family
ID=50442720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502187A Active JP6377123B2 (ja) | 2013-03-14 | 2014-03-13 | 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9758495B2 (enExample) |
| EP (1) | EP2970237B1 (enExample) |
| JP (1) | JP6377123B2 (enExample) |
| AU (1) | AU2014236812B2 (enExample) |
| CA (1) | CA2906538C (enExample) |
| MX (1) | MX374513B (enExample) |
| WO (1) | WO2014151863A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| AU2012316055B2 (en) | 2011-09-27 | 2016-05-12 | Amgen Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| MA53572A1 (fr) | 2013-06-10 | 2021-10-29 | Amgen Inc | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EA202092456A3 (ru) | 2013-11-11 | 2021-09-30 | Эмджен Инк. | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| CN108137507A (zh) | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | 基于mdm2的蛋白水解调节剂和相关的使用方法 |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| EP3535265A4 (en) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| WO2018102725A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| EP3558994A4 (en) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
| EP3658543A1 (en) * | 2017-07-28 | 2020-06-03 | Basf Se | Preparation of substituted 3-aryl-5-trifluoromethyl-1,2,4-oxadiazoles |
| WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
| WO2019038042A1 (en) | 2017-08-21 | 2019-02-28 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR THE CONTROL OF PHYTOPATHOGENIC FUNGI |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| WO2019219464A1 (en) | 2018-05-15 | 2019-11-21 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| ES3061133T3 (en) | 2019-08-26 | 2026-03-31 | Arvinas Operations Inc | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| IL293396B2 (en) | 2019-12-05 | 2026-05-01 | Basf Se | Preparation of modified aromatic carboxamides |
| CN115298163B (zh) | 2020-04-29 | 2024-11-19 | 巴斯夫欧洲公司 | 通过钯催化的羰基化反应制备芳族羧酰胺 |
| EP4143159B1 (en) | 2020-04-29 | 2024-04-10 | Basf Se | Preparation of aromatic carboxyamides by a palladium-catalyzed carbonylation reaction |
| EP4204418A1 (en) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1016828A (en) | 1961-11-13 | 1966-01-12 | Mcneilab Inc | Substituted morpholines and process for preparing same |
| US3518236A (en) | 1967-07-20 | 1970-06-30 | Uniroyal Inc | Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives |
| DE3246148A1 (de) | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JP2604472B2 (ja) | 1989-07-12 | 1997-04-30 | 株式会社クラレ | 重合性組成物 |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| WO1995023135A1 (en) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity |
| CA2517691A1 (en) | 1994-08-19 | 1996-02-29 | Abbott Laboratories | Endothelin antagonists |
| PT885215E (pt) | 1996-02-13 | 2006-08-31 | Abbott Lab | Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina |
| AUPO527597A0 (en) * | 1997-02-24 | 1997-03-20 | Fujisawa Pharmaceutical Co., Ltd. | Novel heterocyclic compounds |
| US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
| TR200000993T2 (tr) | 1997-08-04 | 2000-12-21 | Abbott Laboratories | Endotelin antagonistleri. |
| WO1999031507A1 (en) | 1997-12-18 | 1999-06-24 | Eli Lilly And Company | Peptidomimetic template-based combinatorial libraries |
| US6770658B2 (en) | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| US7214540B2 (en) | 1999-04-06 | 2007-05-08 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
| US6630006B2 (en) | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
| US7195670B2 (en) | 2000-06-27 | 2007-03-27 | California Institute Of Technology | High throughput screening of crystallization of materials |
| US7052545B2 (en) | 2001-04-06 | 2006-05-30 | California Institute Of Technology | High throughput screening of crystallization of materials |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| WO2002042731A2 (en) | 2000-11-20 | 2002-05-30 | Parallel Synthesis Technologies, Inc. | Methods and devices for high throughput crystallization |
| HUP0304058A2 (hu) | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| DE60229059D1 (de) | 2001-05-08 | 2008-11-06 | Univ Yale | Proteomimetische verbindungen und verfahren |
| EP1395560A1 (en) | 2001-05-23 | 2004-03-10 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| CN100486969C (zh) | 2001-12-18 | 2009-05-13 | 霍夫曼-拉罗奇有限公司 | 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用 |
| US6860940B2 (en) | 2002-02-11 | 2005-03-01 | The Regents Of The University Of California | Automated macromolecular crystallization screening |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| EP1753727B1 (en) | 2004-05-18 | 2008-11-19 | F.Hoffmann-La Roche Ag | Novel cis-imidazolines |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| CN101389335A (zh) | 2004-10-18 | 2009-03-18 | 安姆根有限公司 | 噻二唑化合物和使用方法 |
| JP4955646B2 (ja) | 2005-03-16 | 2012-06-20 | エフ．ホフマン−ラ ロシュ アーゲー | シス−２，４，５−トリアリール−イミダゾリン及びそれらの抗癌薬としての使用 |
| ATE511843T1 (de) | 2005-04-04 | 2011-06-15 | Eisai R&D Man Co Ltd | Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz |
| KR20100129331A (ko) | 2005-12-01 | 2010-12-08 | 에프. 호프만-라 로슈 아게 | 항암제로서 사용하기 위한 ｐ53 및 ｍｄｍ2 단백질 간 상호작용의 저해제로서의 2,4,5-트리페닐 이미다졸린 유도체 |
| CN101421265A (zh) | 2006-01-18 | 2009-04-29 | 安姆根有限公司 | 作为蛋白激酶b(pkb)抑制剂的噻唑化合物 |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| CA2656398A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2046328A4 (en) | 2006-07-19 | 2009-10-28 | Univ Georgia Res Found | PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| GB0722769D0 (en) | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| RS54706B1 (sr) | 2007-03-23 | 2016-08-31 | Amgen Inc. | Heterociklična jedinjenja i njihove upotrebe |
| AU2008231384B2 (en) | 2007-03-23 | 2011-09-15 | Amgen Inc. | Heterocyclic compounds and their use |
| MX2009010050A (es) | 2007-03-23 | 2009-10-12 | Amgen Inc | Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k). |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| US8138183B2 (en) | 2007-07-09 | 2012-03-20 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K |
| AU2008276521B2 (en) | 2007-07-17 | 2011-11-03 | Amgen Inc. | Heterocyclic modulators of PKB |
| WO2009011871A2 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
| US7928140B2 (en) | 2007-08-02 | 2011-04-19 | Amgen Inc. | Benzothiazole PI3 kinase modulators for cancer treatment |
| CA2701932C (en) | 2007-10-09 | 2015-10-20 | F. Hoffmann-La Roche Ag | Chiral cis-imidazolines |
| PE20091268A1 (es) | 2007-12-19 | 2009-09-19 | Amgen Inc | Derivados heterociclicos como inhibidores de pi3 quinasa |
| MX2010006457A (es) | 2007-12-19 | 2010-07-05 | Amgen Inc | Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular. |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US20100256191A1 (en) | 2007-12-26 | 2010-10-07 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
| CN102036956A (zh) | 2008-03-21 | 2011-04-27 | 柯罗瑞恩制药有限公司 | 取代的吡咯烷和哌啶化合物、它们的衍生物、以及用于治疗疼痛的方法 |
| MX2010010975A (es) | 2008-04-07 | 2010-11-01 | Amgen Inc | Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular. |
| JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
| CA2734363C (en) | 2008-09-18 | 2016-10-25 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| EP2387570A1 (en) | 2009-01-15 | 2011-11-23 | Amgen, Inc | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| AU2010216239B2 (en) | 2009-02-18 | 2012-06-14 | Amgen Inc. | Indole/benzimidazole compounds as mTOR kinase inhibitors |
| CA2755285C (en) | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| EP2430013B1 (en) | 2009-05-13 | 2014-10-15 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| KR20140015121A (ko) | 2009-06-25 | 2014-02-06 | 암젠 인크 | 헤테로사이클릭 화합물 및 이의 용도 |
| EA201270013A1 (ru) | 2009-06-25 | 2012-06-29 | Амген Инк. | Гетероциклические соединения и их применение |
| EP2445898A2 (en) | 2009-06-25 | 2012-05-02 | Amgen, Inc | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors |
| MX2011013667A (es) | 2009-06-25 | 2012-03-06 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| AU2010288534A1 (en) | 2009-08-26 | 2012-03-15 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| CN102153557B (zh) | 2011-01-21 | 2013-03-20 | 中国科学院上海有机化学研究所 | 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途 |
| AU2012316055B2 (en) | 2011-09-27 | 2016-05-12 | Amgen Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| AU2014219075C1 (en) | 2013-02-19 | 2018-09-06 | Amgen Inc. | Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| CA2902856C (en) | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| MA53572A1 (fr) | 2013-06-10 | 2021-10-29 | Amgen Inc | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
| EA202092456A3 (ru) | 2013-11-11 | 2021-09-30 | Эмджен Инк. | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака |
-
2014
- 2014-03-13 WO PCT/US2014/026584 patent/WO2014151863A1/en not_active Ceased
- 2014-03-13 JP JP2016502187A patent/JP6377123B2/ja active Active
- 2014-03-13 CA CA2906538A patent/CA2906538C/en active Active
- 2014-03-13 MX MX2015012427A patent/MX374513B/es active IP Right Grant
- 2014-03-13 EP EP14716176.4A patent/EP2970237B1/en active Active
- 2014-03-13 US US14/774,645 patent/US9758495B2/en active Active
- 2014-03-13 AU AU2014236812A patent/AU2014236812B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160039774A1 (en) | 2016-02-11 |
| CA2906538C (en) | 2021-02-02 |
| EP2970237B1 (en) | 2017-09-27 |
| CA2906538A1 (en) | 2014-09-25 |
| JP2016513660A (ja) | 2016-05-16 |
| AU2014236812A1 (en) | 2015-09-17 |
| EP2970237A1 (en) | 2016-01-20 |
| WO2014151863A1 (en) | 2014-09-25 |
| MX2015012427A (es) | 2016-01-12 |
| MX374513B (es) | 2025-03-06 |
| US9758495B2 (en) | 2017-09-12 |
| AU2014236812B2 (en) | 2018-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513660A (ja) | 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 | |
| JP6093770B2 (ja) | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 | |
| JP6077695B2 (ja) | 癌の治療用ｍｄｍ２阻害剤としてのピペリジノン誘導体 | |
| JP6266659B2 (ja) | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 | |
| JP6417338B2 (ja) | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 | |
| US11407721B2 (en) | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | |
| WO2013123444A1 (en) | Sulfonyl compounds that interact with glucokinase regulatory protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170222 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170222 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180611 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180710 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180724 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6377123 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |